A detailed history of Hsbc Holdings PLC transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Hsbc Holdings PLC holds 44,006 shares of SNDX stock, worth $738,860. This represents 0.0% of its overall portfolio holdings.

Number of Shares
44,006
Previous 43,597 0.94%
Holding current value
$738,860
Previous $895,000 5.36%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$17.93 - $24.81 $7,333 - $10,147
409 Added 0.94%
44,006 $847,000
Q2 2024

Aug 12, 2024

BUY
$18.82 - $23.79 $75,392 - $95,302
4,006 Added 10.12%
43,597 $895,000
Q1 2024

May 15, 2024

SELL
$19.71 - $24.57 $179,893 - $224,250
-9,127 Reduced 18.73%
39,591 $942,000
Q4 2023

Feb 12, 2024

BUY
$11.39 - $21.67 $554,898 - $1.06 Million
48,718 New
48,718 $1.05 Million

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $950M
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Hsbc Holdings PLC Portfolio

Follow Hsbc Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.